Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | Y014059 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
no adverse event; 1st dose of GARDASIL 9 on 1/8/2025 and 2nd dose on 3/1/2025; This spontaneous report was received from a pharmacist and refers to a 26-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 08-Jan-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (dose, formulation, route of administration, injection site, lot # and expiration date were not reported). On 01-Mar-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) at 0.5 mL (lot #Y014059 was verified to be a valid number, expiration date: 01-Nov-2026) (scheme, formulation, route of administration and injection site were not reported); both doses for prophylaxis (inappropriate schedule of product administration). No additional adverse event was reported.